Tweet
Hi, what is the different Illumina Genome Analyzer I ,II and IIX? I got single end 36bp and 76bp? which system of illumina do they come? thanks
-
-
They're all variants of the same basic platform. Improvements have been made over time to the imaging stage and provisions were made for longer runs by increasing the size of the reagent coolers.
I'm not really sure why it matters which machine a particular dataset came from. If anything it would be more important to know which version of the chemistry was used and which analysis pipeline did the base calling.
I suppose you could tell the difference between a GAII and a GAIIx by looking at the number of tiles in your data (100 for a GAII, 120 for a GAIIx). There's probably some similar metric you can use for a GAI, but we never had one of those so I couldn't tell you what to look for. -
thank you. I always think the difference between them is read length.Originally posted by simonandrews View PostComment
-
The main difference between the GAI and the GAII is the flow cell:it's larger in the GAII.
The main difference between GAII and GAIIx is that GAIIx can acquire data from 120 tiles per lane (only 100 tiles/lane in the GAII). It's due to a modification of the manifold and prism in the GAIIx.
The other difference is the amount of sequencing kits you can load at once on the machine. GAII has tanks than can accept up to 150 ml whereas GAII had to be reloaded every 36 cycles. Nevertheless, the read lengths are the same on the GAII and on the GAIIx.Comment
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment